About Cyclerion Therapeutics, Inc
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer’s disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142
Cyclerion Therapeutics, Inc News and around…
Latest news about Cyclerion Therapeutics, Inc (CYCN) common stock and company :
The recent 14% drop in Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) stock could come as a blow to insiders who...
Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) study enrollment closed; topline data expected in Q2 2022Cognitive Impairment Associated with Schizophrenia (CIAS) study enrollment closed; topline data expected in Q3 2022Alzheimer’s Disease with vascular pat
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney ...
Gainers Enveric Biosciences (NASDAQ:ENVB) shares moved upwards by 11.0% to $0.36 during Tuesday's after-market session. Enveric ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022 Phase 2a study in Alzheimer’s Disease with vascular pathology (ADv) enrollment ongoing CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairmentCAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and ac
Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creationCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next
Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognitionCAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv). “The need for effective new treatments for Alzheimer’s disease is immense, and
Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The ...
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced ...
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of ...
Viewing insider transactions for Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) over the last year, we see that...
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 40.19% to $14.3 during Wednesday's after-market session. At the close, ...
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021. A pre-recorded corporate presentation will be available on-demand beginning on Thursday, Nov. 18 and will remain available for 30 days in the investor section of the Cyclerion w
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS); Topline clinical results expected in H1 2022 CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to d
Infused with $27 million from General Catalyst and Casdin Capital, Beacon Biosignals is planning to capitalize on the resurgence in neuroscience across the biotech field.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.
Truistanalyst Joon Lee hasinitiated coverageofCyclerion Therapeutics Inc(NASDAQ: CYCN) with a Buy ...
Upgrades For Iridium Communications Inc (NASDAQ:IRDM), BWS Financial upgraded the previous rating of Neutral to Buy. Iridium ...
Gainers F-star Therapeutics (NASDAQ:FSTX) shares increased by 18.74% to $7.6 during Wednesday's pre-market session. ...
In this article, we discuss the top stocks recently acquired by David Greenspan’s Slate Path Capital according to analysts. If you want to skip our detailed analysis of Greenspan’s history, investment philosophy, and hedge fund performance, go directly to David Greenspan’s Slate Path Capital is Buying These 5 Stocks. David Greenspan instilled his efforts at […]
Every investor in Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) should be aware of the most powerful shareholder groups...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:TENB) from Hold to Buy. In the second quarter, Tenable ...
Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairmentCAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small molecule soluble guanylate cyclase (sGC) stimulator reduced markers associated with neuroinflammation in multiple precli
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th.Cantor Fitzgerald Virtual Global Healthcare C
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer’s disease therapiesCAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 25-26, 2021. Chris Winrow, Ph.D., Head o
Cyclerion Therapeutics, Inc (CYCN) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
